Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Origin of multiple myeloma found in rare stem cell

04.12.2003


Johns Hopkins Kimmel Cancer Center scientists have identified the cell likely to be responsible for the development of multiple myeloma, a cancer of the bone marrow that destroys bone tissue. The research, published in Blood online, suggests that therapies designed for long-term cure of the disease should target this stem cell, which, unlike other cells, can copy itself and differentiate into one or more specialized cell types.

In their studies to learn why multiple myeloma so often recurs following drug treatment, the investigators uncovered a rare stem cell , occurring in just one out of every 10,000 cells or less than one percent of all myeloma cells.

Working with immune system B-cells, the Johns Hopkins team found that this stem cell gives rise to the malignant bone marrow plasma cells characterized by multiple myeloma.



Current treatments target the malignant plasma cells but may not be effective on the errant multiple myeloma stem cells, allowing the cancer to recur. "Most therapies today are aimed at the cancer you can see, but to cure cancer you have to go after the cells responsible for the disease, similar to how we kill a weed by getting at its roots, not just the part above the ground," explains Richard Jones, M.D., professor and director of bone marrow transplant at the Johns Hopkins Kimmel Cancer Center. "If you cut off the flower and stem of a dandelion, it may look like it has died for a period of time, but the weed eventually will grow back. If you get the root, however, the weed does not grow back."

The scientists found the rare stem cell by looking at markers on the surface of damaged B-cells, which develop into plasma cells that cannot divide and multiply. "We know what the markers are on cancerous plasma cells and the antibodies they make, and we also know the markers on B-cells that are not cancerous. So, we went looking for a B-cell that has the same antibodies, can make copies of itself and mature into cancerous plasma cells," says William Matsui, M.D., assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center.

They found that this multiple myeloma stem cell looks and acts genetically different from the plasma cell.

"Because these two cells are biologically different, we may need two therapies – one to kill the plasma cells, or the visible part of the weed; and one to kill the root – the stem cells," says Matsui. "Treatments that are directed at myeloma plasma cells are likely to produce visible results, but they will be temporary improvements unless we also target the myeloma stem cell."

Therapies for myeloma undergoing study at the Johns Hopkins Kimmel Cancer Center include antibodies that target the stem cells and drugs to make them age prematurely. Cancer stem cells have been found as the culprit in chronic myeloid leukemia, and the scientists believe the same pattern of cancer development may apply to other cancers, including breast cancer, acute myeloid leukemia and acute lymphocytic leukemia.

Multiple myeloma is the second most common blood cancer and strikes more than 14,000 Americans each year. Close to 11,000 will die from the disease.


This research was funded by the National Cancer Institute.

Other participants in this research include Carol Ann Huff, Qiuju Wang, Matthew T. Malehorn, James Barber, Yvette Tanhehco, B. Douglas Smith, and Curt I. Civin from the Johns Hopkins Kimmel Cancer Center.

Vanessa Wasta | EurekAlert!
Further information:
http://www.hopkinsmedicine.org

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>